Accessibility Menu
Avrobio logo

Avrobio(NASDAQ) AVRO

This security has been delisted. This page is retained for historical reference.

Avrobio last closing stock price
MetricPriceDate
Last closeUSD 37.042026-08-19
Avrobio stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0.57%USD 36.832026-08-12
1 month+15.5%USD 32.072026-07-20
3 month+29.87%USD 28.522026-05-21
Year to date+77.56%USD 20.862025-12-31
1 year+56.29%USD 23.702025-08-19
3 year+104.42%USD 18.122023-08-18
5 year-46.32%USD 69.002021-08-20
Since inception-95.51%USD 374.402018-06-21

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

AVRO Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-35.26%

Return on Capital

-33.27%

Return on Assets

-36.19%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$94.93M

EBITDA

-$61.10M

Operating Cash Flow

-$72.14M

Capital Expenditure

-$279.00K

Free Cash Flow

-$72.42M

Cash & ST Invst.

$227.07M

Total Debt

$4.40M

Avrobio Performance Analysis

Avrobio annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Avrobio sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Q22026-06-30N/A
Avrobio annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -29.05-12.9%
20232023-12-31USD -33.7616.2%
20242024-12-31USD -6.83-79.8%
20252025-12-31USD -4.05-40.7%
Avrobio sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-304.7%
Q42025-12-31-1.0%
Q12026-03-31-30.1%
Q22026-06-3011.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

13

N/A

Net Income

-$22.29M

-11.5%

EBITDA

-$24.22M

-32.4%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$227.07M

-21.0%

Total Debt

$4.40M

+126.4%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$2.82M

+1415.6%

Short Term Debt

$1.58M

-10.1%

Return on Assets

-36.19%

N/A

Return on Invested Capital

-41.88%

N/A

Free Cash Flow

-$21.53M

-46.0%

Operating Cash Flow

-$21.45M

-45.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
NEUPNeuphoria Therapeutics Inc.
$3.96+0.64%
BVXVBiondVax Pharmaceuticals Ltd.
$1.36+0.74%
TCDATricida, Inc.
$0.11+0.00%
NBRVFNabriva Therapeutics plc
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
BITOProShares Trust - ProShares Bitcoin ETF
$9.78+0.06%
IBITiShares Bitcoin Trust
$40.97+0.06%
SPCXSpace Exploration Technologies
$131.29-0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.87-0.03%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.